CYP19A1 and breast carcinoma: ZOL prevents osteoporosis in postmenopausal women [166], bone loss in breast cancer patients with bone metastases [167], cancer treatment-related bone loss in premenopausal women with early-stage breast cancer [168], and aromatase inhibitor-related musculoskeletal symptoms in postmenopausal women with breast cancer [169].